What's Going On With Novavax Stock On Friday?

Core Insights - Novavax Inc. reported a fourth-quarter profit of $0.11 per share, a significant improvement from a loss of $0.51 per share a year ago, with revenue reaching $147 million, marking a 67% year-over-year increase [2] - The company projected adjusted total revenue for 2026 to be between $230 million and $270 million, which is below the consensus estimate of $381.22 million [2] - Novavax's R&D and SG&A expenses are expected to be $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 [3] Stock Performance - Novavax shares experienced a decline of 11.30% to $9.93, following a profit-taking trend after a previous rally [6] - The stock is currently trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength despite the recent downturn [4] - Over the past 12 months, shares have shown significant growth and are closer to their 52-week highs than lows [4] Technical Indicators - The Relative Strength Index (RSI) is at 44.45, indicating a neutral position, suggesting the stock is neither overbought nor oversold [5] - The absence of significant MACD crossovers indicates a stable trend without immediate bullish or bearish pressure, suggesting mixed momentum [5] Analyst Consensus - The stock carries a Hold rating with an average price target of $32.62 [6] - Recent analyst actions include HC Wainwright & Co. upgrading to Buy and raising the target to $16.00 [6] - Key resistance level is identified at $11.50, while key support is at $9.00 [6]